Clinical Trial

Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.

Recruiting
View on ClinicalTrials.gov →
Summary
The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-28; most recent amendment 2026-02-10.
Trial Details
NCT Number NCT06016569
Lead Sponsor The Institute of Molecular and Translational Medicine, Czech Republic
Collaborators: Cancer Research Foundation CR
Conditions Lung Cancer
Enrollment 3,200 participants
Start Date 2023-06-01
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-12